Exec-Edge, Author at ExecEdge - Page 5 of 133

Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates

Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates

By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Association 2026 Congress taking place on June 11-14, 2026, in Stockholm, Sweden. The global TENACITY-01 study...

FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases

FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases

By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b of this clinical trial will study CTA313 in patients with systemic...

Highlights: Tech Edge at Pax8 Beyond 2026 in Salt Lake City

Highlights: Tech Edge at Pax8 Beyond 2026 in Salt Lake City

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted firesides live from Pax8 Beyond 2026 at the Salt Palace Convention Center in Salt Lake City, Utah. Interviews included Pax8, SentinelOne, Inc. (NYSE: S), CrowdStrike Holdings, Inc. (Nasdaq: CRWD), among other...

Input your search keywords and press Enter.